Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kazumasa Aoki

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Bioorganic & Medicinal Chemistry|January 16, 2025
Current Japanese pharmaceutical chemistryKazumasa Aoki, Hideko Nagasawa
Drug Discovery Today|April 22, 2022
From traditional to data-driven medicinal chemistry: A case studyRyo Kunimoto, Jürgen Bajorath, Kazumasa Aoki
European Journal of Pharmacology|January 14, 2003
Effects of rhizoxin, a microbial angiogenesis inhibitor, on angiogenic endothelial cell functionsKazumasa Aoki, Kaoru Watanabe, Mayumi Sato, et al.
Scientific Reports|March 4, 2020
Kibi Plateau: A stable-coherent tectonic unit in the active Japanese IslandsTakafumi Sonehara, Koshi Yagi, Hiroyuki Takeshita, et al.
Bioorganic & Medicinal Chemistry Letters|July 20, 2010
Tetrahydropyridine derivatives with inhibitory activity on the production of proinflammatory cytokines: part 3Akira Nakao, Nobuyuki Ohkawa, Takayoshi Nagasaki, et al.
Bioorganic & Medicinal Chemistry Letters|March 30, 2010
Tetrahydropyridine derivatives with inhibitory activity on the production of proinflammatory cytokines: part 2Akira Nakao, Nobuyuki Ohkawa, Takayoshi Nagasaki, et al.
Bioorganic & Medicinal Chemistry Letters|July 15, 2009
Tetrahydropyridine derivatives with inhibitory activity on the production of proinflammatory cytokines: part 1Akira Nakao, Nobuyuki Ohkawa, Takayoshi Nagasaki, et al.
European Journal of Pharmacology|June 16, 2015
Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonistKiyoshi Arai, Tsuyoshi Homma, Yuka Morikawa, et al.
European Journal of Pharmacology|January 4, 2005
R-130823, a novel inhibitor of p38 MAPK, ameliorates hyperalgesia and swelling in arthritis modelsYoshihiro Wada, Tomoko Nakajima-Yamada, Kazuyo Yamada, et al.
FEBS Letters|January 29, 2020
Crystal structure of the mineralocorticoid receptor ligand-binding domain in complex with a potent and selective nonsteroidal blocker, esaxerenone (CS-3150)Mizuki Takahashi, Osamu Ubukata, Tsuyoshi Homma, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Bioorganic & Medicinal Chemistry|January 16, 2025
Current Japanese pharmaceutical chemistryKazumasa Aoki, Hideko Nagasawa
Drug Discovery Today|April 22, 2022
From traditional to data-driven medicinal chemistry: A case studyRyo Kunimoto, Jürgen Bajorath, Kazumasa Aoki
European Journal of Pharmacology|January 14, 2003
Effects of rhizoxin, a microbial angiogenesis inhibitor, on angiogenic endothelial cell functionsKazumasa Aoki, Kaoru Watanabe, Mayumi Sato, et al.
Scientific Reports|March 4, 2020
Kibi Plateau: A stable-coherent tectonic unit in the active Japanese IslandsTakafumi Sonehara, Koshi Yagi, Hiroyuki Takeshita, et al.
Bioorganic & Medicinal Chemistry Letters|July 20, 2010
Tetrahydropyridine derivatives with inhibitory activity on the production of proinflammatory cytokines: part 3Akira Nakao, Nobuyuki Ohkawa, Takayoshi Nagasaki, et al.
Bioorganic & Medicinal Chemistry Letters|March 30, 2010
Tetrahydropyridine derivatives with inhibitory activity on the production of proinflammatory cytokines: part 2Akira Nakao, Nobuyuki Ohkawa, Takayoshi Nagasaki, et al.
Bioorganic & Medicinal Chemistry Letters|July 15, 2009
Tetrahydropyridine derivatives with inhibitory activity on the production of proinflammatory cytokines: part 1Akira Nakao, Nobuyuki Ohkawa, Takayoshi Nagasaki, et al.
European Journal of Pharmacology|June 16, 2015
Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonistKiyoshi Arai, Tsuyoshi Homma, Yuka Morikawa, et al.
European Journal of Pharmacology|January 4, 2005
R-130823, a novel inhibitor of p38 MAPK, ameliorates hyperalgesia and swelling in arthritis modelsYoshihiro Wada, Tomoko Nakajima-Yamada, Kazuyo Yamada, et al.
FEBS Letters|January 29, 2020
Crystal structure of the mineralocorticoid receptor ligand-binding domain in complex with a potent and selective nonsteroidal blocker, esaxerenone (CS-3150)Mizuki Takahashi, Osamu Ubukata, Tsuyoshi Homma, et al.
Pageof 2